Discussions frequently challenge earlier beliefs about cholesterol management, exemplified by comments questioning why niacin didn't reduce cardiovascular events despite improving lipid profiles, and references to negative results in trials like AIM-high. The tone oscillates between skepticism and curiosity, reflecting active engagement with the research's implications but with limited consensus on its clinical significance.
AgreementLow agreement
The discussions generally question the effectiveness of niacin, reflecting some disagreement with previous positive notions, especially pointing out the negative outcomes of clinical trials.
InterestHigh interest
The topics generate high interest, as users are focused on the implications of lipid-raising drugs and the recent study's findings.
EngagementModerate engagement
Participants actively dissect the study's results and previous research, including references to specific trials and biochemical markers, indicating a moderate level of detailed engagement.
ImpactNeutral impact
While the conversations highlight ongoing debates and challenge prior assumptions, the overall influence on clinical practice remains uncertain, leading to a neutral impact score.
Abstract in brief
The study investigated whether adding extended-release niacin to statin therapy would further reduce residual cardiovascular risk in patients with established disease, but the trial was stopped early after 3 years due to lack of evidence showing benefit.
While niacin improved HDL cholesterol and lowered triglyceride and LDL levels, it did not significantly decrease the incidence of major cardiovascular events compared to placebo.
These findings suggest that, despite better lipid profiles, niacin did not provide additional protection against cardiovascular events in patients already on intensive statin therapy.]
36) #Nicotinic_acid was long used due to its favorable effects on #HDL_C, #LDL_C, and #TG.
☝️However, two negative #RCTs (https://t.co/TFFCGTVoUw and https://t.co/EpLwUi00LR ) and its poor tolerability
Listening to someone extoll virtues of Niacin - (B3) .. but then why was AIM-high RCT negative? .. even though niacin group had lower Triglyerides and higher HDL? Cc @CharlesMBrenner
https://t.co/WpPjDBhxao
Feb 21, 2022 · 1 like · 28,287 followersView post →
DF
Dr Alo, DO, FACC
@MohammedAlo · X
@heavensfreckles Yes of course. https://t.co/2TVL7wuC8J
Mar 27, 2025 · 1 like · 12,959 followersView post →
TK
Tejas Kulkarni
@TejasTekk · X
Across major outcome trials that pharmacologically raised HDL-C (torcetrapib, dalcetrapib, niacin ± laropiprant), cardiovascular events were not reduced
https://t.co/Vttl43gSkd
https://t.co/yNNfHLCFxi
https://t.co/wAT1juHIwF
https://t.co/aQdYdFSLb6
https://t.co/cUSC19T2YU
Oct 10, 2025 · 1 like · 4,448 followersView post →
K
Karageorgos
@Karageorgos15 · X
Doctors were Wrong about Cholesterol and Heart Disease https://t.co/iqLiIa2qBM via @YouTube
This video explores the misconception that lowering cholesterol with niacin reduces cardiovascular risk. Although niacin improves lipid profiles, studies show it doesn't significantly decrease major cardiovascular…
Niacin increases HDL cholesterol, but studies show it does not lower cardiovascular events. Improving lipid numbers on paper does not translate to reduced risk in real life. Consult a professional for personalized…
Across major outcome trials that pharmacologically raised HDL-C (torcetrapib, dalcetrapib, niacin ± laropiprant), cardiovascular events were not reduced
https://t.co/Vttl43gSkd
https://t.co/yNNfHLCFxi
https://t.co/wAT1juHIwF
https://t.co/aQdYdFSLb6
https://t.co/cUSC19T2YU
Oct 10, 2025 · 1 like · 4,448 followersView post →
DF
Dr Alo, DO, FACC
@MohammedAlo · X
@heavensfreckles Yes of course. https://t.co/2TVL7wuC8J
Mar 27, 2025 · 1 like · 12,959 followersView post →
CM
cardio-met
@cardiomet_CE · X
36) #Nicotinic_acid was long used due to its favorable effects on #HDL_C, #LDL_C, and #TG.
☝️However, two negative #RCTs (https://t.co/TFFCGTVoUw and https://t.co/EpLwUi00LR ) and its poor tolerability
Listening to someone extoll virtues of Niacin - (B3) .. but then why was AIM-high RCT negative? .. even though niacin group had lower Triglyerides and higher HDL? Cc @CharlesMBrenner
https://t.co/WpPjDBhxao
Feb 21, 2022 · 1 like · 28,287 followersView post →
N
When Cardiovascular Medicines Should Be Discontinued ESC 2024 ...
News
NEJMoa1107579 left-ventricular dysfunction: the CAPRICORN randomised trial. ... https://doi.org/10.1056/NEJMoa0904327 Deprescribing in older adults with ...
Those who lowered LDL/ApoB through diet, how did you do it? : r ...
Reddit
... offsetting the benefits, Attia references the AIM-HIGH trial a few times https://www.nejm.org/doi/full/10.1056/NEJMoa1107579 · willbot858. • 2y ...